Details for Patent: 8,268,848
✉ Email this page to a colleague
Which drugs does patent 8,268,848 protect, and when does it expire?
Patent 8,268,848 protects DAYVIGO and is included in one NDA.
This patent has thirty-six patent family members in thirty-two countries.
Summary for Patent: 8,268,848
| Title: | Cyclopropane compound |
| Abstract: | A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: ##STR00001## wherein Q represents --CH-- or a nitrogen atom, R.sub.1a and R.sub.1b each independently represent a C.sub.1-6 alkyl group and the like, R.sub.1c represents a hydrogen atom and the like, R.sub.2a, R.sub.2b, R.sub.2c and R.sub.2d each independently represent a hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group and the like, R.sub.3a, R.sub.3b and R.sub.3c each independently represent a hydrogen atom, a halogen atom and the like, and R.sub.3d represents a hydrogen atom and the like. |
| Inventor(s): | Terauchi; Taro (Tsukuba, JP), Takemura; Ayumi (Tsukuba, JP), Doko; Takashi (Tokyo, JP), Yoshida; Yu (Tsukuba, JP), Tanaka; Toshiaki (Tsukuba, JP), Sorimachi; Keiichi (Tsukuba, JP), Naoe; Yoshimitsu (Tsukuba, JP), Beuckmann; Carsten (Tsukuba, JP), Kazuta; Yuji (Tsukuba, JP) |
| Assignee: | Eisai R&D Management Co., Ltd. (Tokyo, JP) |
| Application Number: | 13/237,205 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,268,848
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE | ⤷ Try a Trial | ||
| Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-002 | Apr 7, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,268,848
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2010-211629 | Sep 22, 2010 |
International Family Members for US Patent 8,268,848
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 083060 | ⤷ Try a Trial | |||
| Australia | 2011304285 | ⤷ Try a Trial | |||
| Brazil | 112013006594 | ⤷ Try a Trial | |||
| Canada | 2811895 | ⤷ Try a Trial | |||
| Chile | 2013000784 | ⤷ Try a Trial | |||
| China | 103153963 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
